CARNITINE
"In some of the studies, L-carnitine therapy was subsequently given for six months to a year, suggesting a possible role not only in acute management but also secondary prevention, according to the authors, led by Dr James J DiNicolantonio (Wegmans Pharmacy, Ithaca, NY)
The apparent survival gains from L-carnitine, which were only modestly significant, seemed to come from infarct-size limitation and cardiomyocyte membrane stabilization, with chronic improvements in cellular energy metabolism, according to their report published online today in the Mayo Clinic Proceedings."
THE ATTRACTION HERE IS ITS RELATION TO THE MTOR
THEY BOTH ACT ON GLUCOSE METABOLISM!

AVANDIA

"Rosiglitazone is a diabetes drug from the thiazolidinedione class; in September 2010, it was suspended by the European Medicines Agency (EMA) because it deemed that the product's cardiovascular risk outweighed its benefits.
At the same time, the FDA deemed there was "a signal of harm" but decided not to suspend the drug. Instead it requested readjudication of the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) study at the individual patient-data level. The agency also required that rosiglitazone-containing medicines be subject to a risk evaluation and mitigation strategy (REMS) program to ensure the safe use of the medicine in patients with no other options. (MEDSCAPE)

was avandia going to be pulled from the market? that was the 12 millions question in the article...
don't kill the messenger!